Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO) (HW794036)

Name: Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO)
Brand: abinScience
SKU: HW794036
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HW794036
Description	Anti-Human Flt-3/Flk-2 Reference Antibody (IMC-EB10, RUO) (HW794036) is a human monoclonal antibody detecting Flt-3/Flk-2. Expressed in Mammalian cells.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG
ID de clone	IMC-EB10
Activité biologique	IMC-EB10 (10 ug/mL, 1 h) reduces FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK in Hb1119 and SEM-K2 cells, but activates them in REH and RS411 cells [1]. IMC-EB10 (10 ug/mL, 1 h) activates FLT3 and downstream Akt in ALLs [1]. IMC-EB10 (0.4-200 nM, 1 h) inhibits FLT3-Fc-induced phosphorylation of wild-type FLT3 and ligand-independent constitutive phosphorylation of ITD-mutant FLT3 in EOL-1, EM3, BaF3-ITD and MV4;11 cells [4]. IMC-EB10 (0.4-200 nM, 1 h) inhibits FLT3-Fc-induced phosphorylation of MAPK, AKT and Stat5 in EOL-1, EM3, BaF3-ITD and MV4;11 cells [4]. IMC-EB10 (1.5-100 nM, 1 h) inhibits proliferation of FLT3-Fc-induced proliferation of EOL-1 and BaF3-ITD cells [4]. Western Blot Analysis [1] Cell Line: Hb1119, SEM-K2 cells Concentration: 10 ug/mL Incubation Time: 1 h Result: Reduced FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK. Western Blot Analysis [1] Cell Line: REH, RS411 cells Concentration: 10 ug/mL Incubation Time: 1 h Result: Activated FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK. Western Blot Analysis [1] Cell Line: ALLs Concentration: 10 ug/mL Incubation Time: 1 h Result: Activated FLT3 and downstream Akt. . Blocked the phosphorylation and constitutive phosphorylation of MAPK, inhibited FL-induced phosphorylation of AKT and Stat5 phosphorylation in EOL-1 and BaF3-ITD cells. Parmacokinetics Species Dose Route T 1/2 AUC 0-inf Mice [2] 20 mg/kg i.p. 96 h 38327 ug·h/mL IMC-EB10 (400 ug/10 mg/kg, i.p.
Système d'expression	Mammalian cells
Cible	FLT3, Stem cell tyrosine kinase 1, Fetal liver kinase-2, STK-1, STK1, FLK2, CD135, Receptor-type tyrosine-protein kinase FLT3, Fms-like tyrosine kinase 3, FL cytokine receptor, FLK-2, FLT-3
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P36888
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	IMC-EB10
Contexte	Receptor-type tyrosine-protein kinase FLT3 (CD135) is a ~112 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B.
Reférences	1. Piloto O, et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-51 [HW794036] 2. Erik Corcoran, et al. Abstract #2923: Preclinical pharmacokinetic and pharmacodynamic evaluation of the anti-FLT3 monoclonal antibody IMC-EB10. Cancer Res 1 May 2009; 69 (9_Supplement): 2923. [HW794036] 3. David Surguladze, et al. Synergistic Anti-Leukemic Effect of Combination Therapy with Anti-FLT3 Antibody.IMC-EB10 and Methotrexate,Blood,Volume 112, Issue 11,2008,Page 3964,ISSN 0006-4971, [HW794036] 4. Li Y, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood.2004 Aug 15;104(4):1137-44. View More [HW794036]
Note	For research use only. Not suitable for clinical or therapeutic use.